Revance Therapeutics Gains FDA Approval for RHA® Dynamic Volume in Aesthetic Treatments
- Revance Therapeutics and Teoxane received FDA approval for RHA® Dynamic Volume, designed for cheek augmentation in adults.
- RHA® Dynamic Volume showed similar results to Juvéderm® Voluma® XC with fewer treatment sessions and high patient satisfaction.
- Revance emphasizes patient safety with RHA® Dynamic Volume, showcasing a favorable safety profile and commitment to innovative aesthetic solutions.
Revance Therapeutics and Teoxane Secure FDA Approval for RHA® Dynamic Volume
Revance Therapeutics, in collaboration with Teoxane, celebrates a significant milestone with the recent FDA approval of RHA® Dynamic Volume, a new addition to the Teoxane RHA® Collection. This innovative product is specifically designed for cheek augmentation and aims to address age-related midface contour deficiencies in adults aged 22 and older. Slated for launch in the first quarter of 2026, RHA® Dynamic Volume, previously known as RHA® 4 Mepi, represents a leap forward in aesthetic treatments, enhancing facial contours while providing essential structural support.
The approval is underpinned by promising results from a robust 52-week Phase III clinical trial, which directly compares RHA® Dynamic Volume to the established Juvéderm® Voluma® XC. The findings reveal that RHA® Dynamic Volume delivers similar aesthetic outcomes with fewer required treatment sessions and touch-ups, a key advantage for patients seeking effective solutions with minimal disruption. Remarkably, over 94% of participants reported satisfaction with the natural appearance and sensation of their cheeks, with no perceived limitations in facial movement even one year after treatment. The study utilized a balanced volume restoration technique, effectively treating both superficial and deep fat layers in 75% of subjects, showcasing the product's versatility and efficacy.
Safety is paramount in the aesthetics industry, and RHA® Dynamic Volume demonstrates a favorable safety profile, with no serious treatment-related adverse events reported during the trial. This outcome reinforces the commitment of Revance to not only innovate but also ensure patient safety and satisfaction. Nadeem Moiz, CEO of Revance, emphasizes the company's dedication to addressing diverse patient needs through groundbreaking advancements in aesthetic treatments. The approval of RHA® Dynamic Volume marks a pivotal moment for Revance, further solidifying its position as a leader in the aesthetic industry and enhancing its portfolio of innovative offerings.
In addition to this notable approval, Revance’s strategic focus on cutting-edge formulations positions the company to meet the evolving demands of the aesthetic market. By leveraging advanced technologies such as Preserved Network Technology (PNT), which maintains the natural structure of hyaluronic acid without heat, Revance aims to provide superior patient outcomes and satisfaction.
As the aesthetic landscape continues to evolve, Revance Therapeutics remains at the forefront, committed to delivering innovative solutions that cater to the increasing demands for safe and effective cosmetic treatments. The anticipated launch of RHA® Dynamic Volume is expected to resonate well with both providers and patients, reinforcing Revance’s role as a key player in the industry.
